Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging

Testosterone use as anabolic therapy is controversial. Here, meta-analyses show that testosterone increases skeletal muscle mass and strength in androgen-deficient young men, older men and men with chronic illness; these data provide a compelling rationale for the development of selective androgen r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature clinical practice. Endocrinology & metabolism 2006-03, Vol.2 (3), p.146-159
Hauptverfasser: Bhasin, Shalender, Calof, Olga M, Storer, Thomas W, Lee, Martin L, Mazer, Norman A, Jasuja, Ravi, Montori, Victor M, Gao, Wenqing, Dalton, James T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 159
container_issue 3
container_start_page 146
container_title Nature clinical practice. Endocrinology & metabolism
container_volume 2
creator Bhasin, Shalender
Calof, Olga M
Storer, Thomas W
Lee, Martin L
Mazer, Norman A
Jasuja, Ravi
Montori, Victor M
Gao, Wenqing
Dalton, James T
description Testosterone use as anabolic therapy is controversial. Here, meta-analyses show that testosterone increases skeletal muscle mass and strength in androgen-deficient young men, older men and men with chronic illness; these data provide a compelling rationale for the development of selective androgen receptor modulators that mimic testosterone's effects without its side effects. Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with β-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging. Key Points Meta-analyses of clinical trials provide unequivocal evidence that testosterone administration increases skeletal muscle mass, muscle strength, and leg power; these anabolic effects of testosterone are dose-related The effects of testosterone supplementation on physical function and clinical outcomes in older men with physical dysfunction and in men with chronic illness are unknown Testosterone induces skeletal muscle fiber hypertrophy and increases the number of satellite cells Testosterone increases muscle mass and decreases fat mass by promoting the diff
doi_str_mv 10.1038/ncpendmet0120
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2072878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188737079</galeid><sourcerecordid>A188737079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c547t-5eb7715098bd4b111f2c3b0531f9f3f5f22abbbaf411a38f352859f567a1402c3</originalsourceid><addsrcrecordid>eNp1ks9rHSEQx5fS0qRpj70WoedN_LE-3R4KIf0VCPTSnkXdcZ9hV7fqBvLf1yaP9_IgRcFx5jsfZnSa5j3B5wQzeRHsAmGYoWBC8YvmlIiOt5KJ7uXe3mxOmjc532LcSUrI6-aEbHpGqehOm_svaR3Rdch-3JZPqEAuMRdIMQDSYUAZJrDF3z3cUhwhoAQWlhITmuOwTrpaGem6gzZx8haVLSS9eMjIVZHdVlb1-mkKkPMDVI8-jG-bV05PGd7tzrPm97evv65-tDc_v19fXd60lneitByMEITjXpqhM4QQRy0zmDPiesccd5RqY4x2HSGaScc4lbx3fCM06XDVnjWfH7nLamYYLISS9KSW5Ged7lXUXh1Hgt-qMd4pigWVQlbAxx0gxT9rfSB1G9cUas2KCCm46DGlB9WoJ1A-uFhhdvbZqksipWACi76qzp9R1TXA7G19dOer_yihfUywKeacwO0LJ1j9GwB1NABV_-Fptwf17scPFeQaCiOkJ938h7hrLOiyJtgTj1V_ASdfzK8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1787579022</pqid></control><display><type>article</type><title>Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Bhasin, Shalender ; Calof, Olga M ; Storer, Thomas W ; Lee, Martin L ; Mazer, Norman A ; Jasuja, Ravi ; Montori, Victor M ; Gao, Wenqing ; Dalton, James T</creator><creatorcontrib>Bhasin, Shalender ; Calof, Olga M ; Storer, Thomas W ; Lee, Martin L ; Mazer, Norman A ; Jasuja, Ravi ; Montori, Victor M ; Gao, Wenqing ; Dalton, James T</creatorcontrib><description>Testosterone use as anabolic therapy is controversial. Here, meta-analyses show that testosterone increases skeletal muscle mass and strength in androgen-deficient young men, older men and men with chronic illness; these data provide a compelling rationale for the development of selective androgen receptor modulators that mimic testosterone's effects without its side effects. Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with β-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging. Key Points Meta-analyses of clinical trials provide unequivocal evidence that testosterone administration increases skeletal muscle mass, muscle strength, and leg power; these anabolic effects of testosterone are dose-related The effects of testosterone supplementation on physical function and clinical outcomes in older men with physical dysfunction and in men with chronic illness are unknown Testosterone induces skeletal muscle fiber hypertrophy and increases the number of satellite cells Testosterone increases muscle mass and decreases fat mass by promoting the differentiation of mesenchymal multipotent cells into myogenic lineage and inhibiting their differentiation into the adipogenic lineage An increase in hematocrit and increased risk of detection of prostate events are the most frequent adverse effects of testosterone administration in older men; the anabolic applications of testosterone are constrained by dose-limiting adverse events and concerns about long-term effects on the prostate and cardiovascular risk Nonsteroidal selective androgen-receptor modulators that are free of adverse effects of testosterone and are preferentially anabolic hold great promise as anabolic therapies</description><identifier>ISSN: 1745-8366</identifier><identifier>ISSN: 1759-5029</identifier><identifier>EISSN: 1745-8374</identifier><identifier>EISSN: 1759-5037</identifier><identifier>DOI: 10.1038/ncpendmet0120</identifier><identifier>PMID: 16932274</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Aging ; Aging - drug effects ; Androgens ; Antiandrogens ; Body composition ; Care and treatment ; Chronic Disease - drug therapy ; Chronic diseases ; Chronic illnesses ; Chronic obstructive pulmonary disease ; Dosage and administration ; Drug Design ; Drug dosages ; Endocrinology ; Health aspects ; Health care ; HIV ; Hormone Replacement Therapy ; Human immunodeficiency virus ; Humans ; Medicine ; Medicine &amp; Public Health ; Meta-analysis ; Middle age ; Muscle strength ; Muscle, Skeletal - drug effects ; Musculoskeletal system ; Organ Specificity ; Prostate ; Receptors, Androgen - drug effects ; review-article ; Testosterone ; Testosterone - adverse effects ; Testosterone - pharmacology ; Testosterone - therapeutic use</subject><ispartof>Nature clinical practice. Endocrinology &amp; metabolism, 2006-03, Vol.2 (3), p.146-159</ispartof><rights>Springer Nature Limited 2006</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Mar 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c547t-5eb7715098bd4b111f2c3b0531f9f3f5f22abbbaf411a38f352859f567a1402c3</citedby><cites>FETCH-LOGICAL-c547t-5eb7715098bd4b111f2c3b0531f9f3f5f22abbbaf411a38f352859f567a1402c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,2727,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16932274$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bhasin, Shalender</creatorcontrib><creatorcontrib>Calof, Olga M</creatorcontrib><creatorcontrib>Storer, Thomas W</creatorcontrib><creatorcontrib>Lee, Martin L</creatorcontrib><creatorcontrib>Mazer, Norman A</creatorcontrib><creatorcontrib>Jasuja, Ravi</creatorcontrib><creatorcontrib>Montori, Victor M</creatorcontrib><creatorcontrib>Gao, Wenqing</creatorcontrib><creatorcontrib>Dalton, James T</creatorcontrib><title>Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging</title><title>Nature clinical practice. Endocrinology &amp; metabolism</title><addtitle>Nat Rev Endocrinol</addtitle><addtitle>Nat Clin Pract Endocrinol Metab</addtitle><description>Testosterone use as anabolic therapy is controversial. Here, meta-analyses show that testosterone increases skeletal muscle mass and strength in androgen-deficient young men, older men and men with chronic illness; these data provide a compelling rationale for the development of selective androgen receptor modulators that mimic testosterone's effects without its side effects. Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with β-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging. Key Points Meta-analyses of clinical trials provide unequivocal evidence that testosterone administration increases skeletal muscle mass, muscle strength, and leg power; these anabolic effects of testosterone are dose-related The effects of testosterone supplementation on physical function and clinical outcomes in older men with physical dysfunction and in men with chronic illness are unknown Testosterone induces skeletal muscle fiber hypertrophy and increases the number of satellite cells Testosterone increases muscle mass and decreases fat mass by promoting the differentiation of mesenchymal multipotent cells into myogenic lineage and inhibiting their differentiation into the adipogenic lineage An increase in hematocrit and increased risk of detection of prostate events are the most frequent adverse effects of testosterone administration in older men; the anabolic applications of testosterone are constrained by dose-limiting adverse events and concerns about long-term effects on the prostate and cardiovascular risk Nonsteroidal selective androgen-receptor modulators that are free of adverse effects of testosterone and are preferentially anabolic hold great promise as anabolic therapies</description><subject>Aging</subject><subject>Aging - drug effects</subject><subject>Androgens</subject><subject>Antiandrogens</subject><subject>Body composition</subject><subject>Care and treatment</subject><subject>Chronic Disease - drug therapy</subject><subject>Chronic diseases</subject><subject>Chronic illnesses</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Dosage and administration</subject><subject>Drug Design</subject><subject>Drug dosages</subject><subject>Endocrinology</subject><subject>Health aspects</subject><subject>Health care</subject><subject>HIV</subject><subject>Hormone Replacement Therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Meta-analysis</subject><subject>Middle age</subject><subject>Muscle strength</subject><subject>Muscle, Skeletal - drug effects</subject><subject>Musculoskeletal system</subject><subject>Organ Specificity</subject><subject>Prostate</subject><subject>Receptors, Androgen - drug effects</subject><subject>review-article</subject><subject>Testosterone</subject><subject>Testosterone - adverse effects</subject><subject>Testosterone - pharmacology</subject><subject>Testosterone - therapeutic use</subject><issn>1745-8366</issn><issn>1759-5029</issn><issn>1745-8374</issn><issn>1759-5037</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1ks9rHSEQx5fS0qRpj70WoedN_LE-3R4KIf0VCPTSnkXdcZ9hV7fqBvLf1yaP9_IgRcFx5jsfZnSa5j3B5wQzeRHsAmGYoWBC8YvmlIiOt5KJ7uXe3mxOmjc532LcSUrI6-aEbHpGqehOm_svaR3Rdch-3JZPqEAuMRdIMQDSYUAZJrDF3z3cUhwhoAQWlhITmuOwTrpaGem6gzZx8haVLSS9eMjIVZHdVlb1-mkKkPMDVI8-jG-bV05PGd7tzrPm97evv65-tDc_v19fXd60lneitByMEITjXpqhM4QQRy0zmDPiesccd5RqY4x2HSGaScc4lbx3fCM06XDVnjWfH7nLamYYLISS9KSW5Ged7lXUXh1Hgt-qMd4pigWVQlbAxx0gxT9rfSB1G9cUas2KCCm46DGlB9WoJ1A-uFhhdvbZqksipWACi76qzp9R1TXA7G19dOer_yihfUywKeacwO0LJ1j9GwB1NABV_-Fptwf17scPFeQaCiOkJ938h7hrLOiyJtgTj1V_ASdfzK8</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Bhasin, Shalender</creator><creator>Calof, Olga M</creator><creator>Storer, Thomas W</creator><creator>Lee, Martin L</creator><creator>Mazer, Norman A</creator><creator>Jasuja, Ravi</creator><creator>Montori, Victor M</creator><creator>Gao, Wenqing</creator><creator>Dalton, James T</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20060301</creationdate><title>Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging</title><author>Bhasin, Shalender ; Calof, Olga M ; Storer, Thomas W ; Lee, Martin L ; Mazer, Norman A ; Jasuja, Ravi ; Montori, Victor M ; Gao, Wenqing ; Dalton, James T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c547t-5eb7715098bd4b111f2c3b0531f9f3f5f22abbbaf411a38f352859f567a1402c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aging</topic><topic>Aging - drug effects</topic><topic>Androgens</topic><topic>Antiandrogens</topic><topic>Body composition</topic><topic>Care and treatment</topic><topic>Chronic Disease - drug therapy</topic><topic>Chronic diseases</topic><topic>Chronic illnesses</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Dosage and administration</topic><topic>Drug Design</topic><topic>Drug dosages</topic><topic>Endocrinology</topic><topic>Health aspects</topic><topic>Health care</topic><topic>HIV</topic><topic>Hormone Replacement Therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Meta-analysis</topic><topic>Middle age</topic><topic>Muscle strength</topic><topic>Muscle, Skeletal - drug effects</topic><topic>Musculoskeletal system</topic><topic>Organ Specificity</topic><topic>Prostate</topic><topic>Receptors, Androgen - drug effects</topic><topic>review-article</topic><topic>Testosterone</topic><topic>Testosterone - adverse effects</topic><topic>Testosterone - pharmacology</topic><topic>Testosterone - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bhasin, Shalender</creatorcontrib><creatorcontrib>Calof, Olga M</creatorcontrib><creatorcontrib>Storer, Thomas W</creatorcontrib><creatorcontrib>Lee, Martin L</creatorcontrib><creatorcontrib>Mazer, Norman A</creatorcontrib><creatorcontrib>Jasuja, Ravi</creatorcontrib><creatorcontrib>Montori, Victor M</creatorcontrib><creatorcontrib>Gao, Wenqing</creatorcontrib><creatorcontrib>Dalton, James T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature clinical practice. Endocrinology &amp; metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bhasin, Shalender</au><au>Calof, Olga M</au><au>Storer, Thomas W</au><au>Lee, Martin L</au><au>Mazer, Norman A</au><au>Jasuja, Ravi</au><au>Montori, Victor M</au><au>Gao, Wenqing</au><au>Dalton, James T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging</atitle><jtitle>Nature clinical practice. Endocrinology &amp; metabolism</jtitle><stitle>Nat Rev Endocrinol</stitle><addtitle>Nat Clin Pract Endocrinol Metab</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>2</volume><issue>3</issue><spage>146</spage><epage>159</epage><pages>146-159</pages><issn>1745-8366</issn><issn>1759-5029</issn><eissn>1745-8374</eissn><eissn>1759-5037</eissn><abstract>Testosterone use as anabolic therapy is controversial. Here, meta-analyses show that testosterone increases skeletal muscle mass and strength in androgen-deficient young men, older men and men with chronic illness; these data provide a compelling rationale for the development of selective androgen receptor modulators that mimic testosterone's effects without its side effects. Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with β-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging. Key Points Meta-analyses of clinical trials provide unequivocal evidence that testosterone administration increases skeletal muscle mass, muscle strength, and leg power; these anabolic effects of testosterone are dose-related The effects of testosterone supplementation on physical function and clinical outcomes in older men with physical dysfunction and in men with chronic illness are unknown Testosterone induces skeletal muscle fiber hypertrophy and increases the number of satellite cells Testosterone increases muscle mass and decreases fat mass by promoting the differentiation of mesenchymal multipotent cells into myogenic lineage and inhibiting their differentiation into the adipogenic lineage An increase in hematocrit and increased risk of detection of prostate events are the most frequent adverse effects of testosterone administration in older men; the anabolic applications of testosterone are constrained by dose-limiting adverse events and concerns about long-term effects on the prostate and cardiovascular risk Nonsteroidal selective androgen-receptor modulators that are free of adverse effects of testosterone and are preferentially anabolic hold great promise as anabolic therapies</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>16932274</pmid><doi>10.1038/ncpendmet0120</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1745-8366
ispartof Nature clinical practice. Endocrinology & metabolism, 2006-03, Vol.2 (3), p.146-159
issn 1745-8366
1759-5029
1745-8374
1759-5037
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2072878
source MEDLINE; Nature; Alma/SFX Local Collection
subjects Aging
Aging - drug effects
Androgens
Antiandrogens
Body composition
Care and treatment
Chronic Disease - drug therapy
Chronic diseases
Chronic illnesses
Chronic obstructive pulmonary disease
Dosage and administration
Drug Design
Drug dosages
Endocrinology
Health aspects
Health care
HIV
Hormone Replacement Therapy
Human immunodeficiency virus
Humans
Medicine
Medicine & Public Health
Meta-analysis
Middle age
Muscle strength
Muscle, Skeletal - drug effects
Musculoskeletal system
Organ Specificity
Prostate
Receptors, Androgen - drug effects
review-article
Testosterone
Testosterone - adverse effects
Testosterone - pharmacology
Testosterone - therapeutic use
title Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A33%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20Insight:%20testosterone%20and%20selective%20androgen%20receptor%20modulators%20as%20anabolic%20therapies%20for%20chronic%20illness%20and%20aging&rft.jtitle=Nature%20clinical%20practice.%20Endocrinology%20&%20metabolism&rft.au=Bhasin,%20Shalender&rft.date=2006-03-01&rft.volume=2&rft.issue=3&rft.spage=146&rft.epage=159&rft.pages=146-159&rft.issn=1745-8366&rft.eissn=1745-8374&rft_id=info:doi/10.1038/ncpendmet0120&rft_dat=%3Cgale_pubme%3EA188737079%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1787579022&rft_id=info:pmid/16932274&rft_galeid=A188737079&rfr_iscdi=true